Skip to main navigation Skip to search Skip to main content

Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline

  • T. Banaschewski
  • , D. Coghill
  • , P. Santosh
  • , A. Zuddas
  • , P. Asherson
  • , J. Buitelaar
  • , M. Danckaerts
  • , M. Döpfner
  • , S.V. Faraone
  • , A. Rothenberger
  • , J.A. Sergeant
  • , H.C. Steinhausen
  • , E.J.S. Sonuga-Barke
  • , E. Taylor

Research output: Contribution to JournalArticleAcademicpeer-review

1427 Downloads (Pure)

Abstract

A systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder is reported, giving effect sizes and numbers-to-treat for extended-release stimulant preparations and atomoxetine (ATX). A panel of experts from several European countries used the review to make recommendations about the use of these drugs in practice, and conclusions are reported: (1) Long-acting preparations should be available and used; (2) They should not replace short-acting drugs (which will be the initial treatment for many children for reasons of cost and flexibility of dosing). Individual clinical choice is needed. (3) Both ATX and extended-release preparations of stimulants should be available. The choice will depend upon the circumstances, and detailed recommendations are made. © 2006 Steinkopff Verlag.
Original languageEnglish
Pages (from-to)476-495
Number of pages21
JournalEuropean Child and Adolescent Psychiatry
Volume15
Issue number8
DOIs
Publication statusPublished - 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline'. Together they form a unique fingerprint.

Cite this